Xinhua News Agency, Beijing, July 28 (Xiao Han) - Viral hepatitis is a major infectious disease that seriously endangers the health of the people and is an important public health issue. In recent years, China has made great achievements in the prevention and treatment of viral hepatitis. However, due to the large number of hepatitis infected people and the heavy burden of Disease burden, the prevention and treatment of hepatitis still has a long way to go. The report of the 20th National Congress of the Communist Party of China pointed out that strengthening the construction of major epidemic prevention and treatment systems and emergency response capabilities can effectively curb the spread of major infectious diseases. July 28th is the 13th "World Hepatitis Day", and this year's promotional theme in China is "Adhere to early prevention, strengthen testing and detection, and standardize antiviral treatment". Recently, Xinhuanet interviewed academicians of the CAE Member, Professor Zhuang Hui of the Peking University Medical Department, and Professor Wang Fusheng of the CAS Member and the Fifth Medical Center of the PLA General Hospital, inviting two experts to analyze the new progress of viral hepatitis research from the perspective of disease prevention and treatment. China has the technical conditions to eliminate hepatitis. hepatitis B has brought a great burden to the world's health. The World Health Organization (WHO) has proposed to eliminate the public health hazards of viral hepatitis by 2030, with specific goals including reducing the incidence of new viral hepatitis by 90%, reducing mortality by 65%, and achieving diagnostic and treatment rates of 90% and 80%, respectively. Viral hepatitis is one of the important public health issues that pose a threat to human health. Over the years, China has adhered to the principles of government leadership, departmental collaboration, and social participation, implemented a comprehensive prevention and control strategy that prioritizes prevention and combines prevention and control, and comprehensively carried out the prevention and control of viral hepatitis. All work has made positive progress. Academician of the CAE Member and Academician Zhuang Hui, Professor of Peking University's Medical Department, introduced that in order to achieve the goal of eliminating viral hepatitis as soon as possible, the World Health Organization proposed five key measures, including the proportion of HBV infected people receiving diagnosis and treatment and the proportion of HCV infected people receiving diagnosis and treatment, the timely vaccination rate of newborn babies and the coverage rate of children's hepatitis B vaccine (three shots), the number of needles and syringes provided to drug injecting people Blood safety and safe injection. "From the perspective of vaccine coverage, the first and three hepatitis B vaccine coverage rates of newborns in China have exceeded the World Health Organization's goal of 2030." Academician Zhuang Hui introduced that the coverage rates of hepatitis B vaccine and hepatitis A vaccine for school-age children in China have reached more than 90%, and the newborns born to hepatitis B surface antigen positive pregnant women have been vaccinated with hepatitis B vaccine and hepatitis B immunoglobulin free of charge, To achieve full coverage of prevention of mother to child transmission of hepatitis B. Eliminating unnecessary invasive diagnostic and therapeutic procedures, blood transfusion and Drug injection are also effective measures to prevent hepatitis virus infection. Academician Zhuang Hui said that since 2015, China has conducted hepatitis C virus DNA testing for hepatitis B B virus surface antigen negative blood donors and hepatitis C virus RNA testing for hepatitis C antibody negative blood donors, greatly reducing the risk of hepatitis B and hepatitis C virus infection caused by blood transfusion and blood products. "At present, China has the technical conditions to carry out the action to eliminate the harm of viral hepatitis. It is worth noting that the diagnosis rate and treatment rate of chronic hepatitis B in China are only 22.1% and 15%, respectively. In the future, we should continue to expand screening efforts